Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy

Fahira, Alistia Ilmiah; Amalia, Riezki; Barliana, Melisa Intan; Gatera, Vesara Ardhe; Abdulah, Rizky

doi:10.2147/bctt.s350403

Cited by 22 publications

(28 citation statements)

References 65 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With over a dozen (almost all of which are PEG-based) PDCs having market approval at the time of publishing for a variety of uses [ 8 ]. Polyethylenimine (PEI), a commonly used transfection reagent for the introduction of genetic material into mammalian cells, also has the potential as a delivery agent for drugs [ 14 ]. So far, it has mainly been described for the delivery of nucleic acids such as plasmid DNA [ 15 ] with several linear PEI-based formulations being evaluated in clinical trials [ 15 ].…”

Section: Introductionmentioning

confidence: 99%

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells

McCartin

Dussouillez

Bernhard

et al. 2022

Cancers

View full text Add to dashboard Cite

The difficulty involved in the treatment of many tumours due to their recurrence and resistance to chemotherapy is tightly linked to the presence of cancer stem cells (CSCs). This CSC sub-population is distinct from the majority of cancer cells of the tumour bulk. Indeed, CSCs have increased mitochondrial mass that has been linked to increased sensitivity to mitochondrial targeting compounds. Thus, a platinum-based polyethylenimine (PEI) polymer–drug conjugate (PDC) was assessed as a potential anti-CSC therapeutic since it has previously displayed mitochondrial accumulation. Our results show that CSCs have increased specific sensitivity to the PEI carrier and to the PDC. The mechanism of cell death seems to be necrotic in nature, with an absence of apoptotic markers. Cell death is accompanied by the induction of a protective autophagy. The interference in the balance of this pathway, which is highly important for CSCs, may be responsible for a partial reversion of the stem-like phenotype observed with prolonged PEI and PDC treatment. Several markers also indicate the cell death mode to be capable of inducing an anti-cancer immune response. This study thus indicates the potential therapeutic perspectives of polycations against CSCs.

show abstract

Section: Introductionmentioning

confidence: 99%

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells

McCartin

Dussouillez

Bernhard

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Polyethyleneimine (PEI), a cationic polymer, has been extensively studied as an anticancer drug delivery carrier ( Fahira et al, 2022 ). α-naphthoflavone (ANF) is a CYP1B1 inhibitor that can reduce the multidrug resistance (MDR) of cancer cells to DTX by inhibiting the expression of CYP1B1 ( Cui et al, 2015 ).…”

Section: Ha Hybrid Nddssmentioning

confidence: 99%

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Jia

Chen

Wang

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy among females worldwide, and high resistance to drugs and metastasis rates are the leading causes of death in BC patients. Releasing anti-cancer drugs precisely to the tumor site can improve the efficacy and reduce the side effects on the body. Natural polymers are attracting extensive interest as drug carriers in treating breast cancer. Hyaluronic acid (HA) is a natural polysaccharide with excellent biocompatibility, biodegradability, and non-immunogenicity and is a significant component of the extracellular matrix. The CD44 receptor of HA is overexpressed in breast cancer cells and can be targeted to breast tumors. Therefore, many researchers have developed nano drug delivery systems (NDDS) based on the CD44 receptor tumor-targeting properties of HA. This review examines the application of HA in NDDSs for breast cancer in recent years. Based on the structural composition of NDDSs, they are divided into HA NDDSs, Modified HA NDDSs, and HA hybrid NDDSs.

show abstract

“…Ryu and co-workers [56] used branched PEI 25 kDa (BPEI-25k) to deliver CRISPR/Cas9 plasmids to Neuro2a cells, and the polymer/plasmid complex showed > 70% transfection e ciency with > 20% Nuero2a cells demonstrated indels in the targeted genes, which is compatible to commercial reagents. Unfortunately, the cytotoxicity of PEI was highlighted due to the high density of cationic charge, and the in vivo and clinical applications of PEI have been restricted [57]. New polymers or combinations of polymers with less toxicity are currently under development for CRISPR/Cas9 system delivery [58].…”

Section: Strategies For Crispr/cas9 Deliverymentioning

confidence: 99%

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Sinclair

Begum

Dai

et al. 2022

Preprint

View full text Add to dashboard Cite

The CRISPR (clustered regularly interspaced short palindromic repeats)/Cas9 genome editing system has been a major technological breakthrough that has brought revolutionary changes to genome editing for therapeutic and diagnostic purposes and precision medicine. With the advent of the CRISPR/Cas9 system, one of the critical limiting factors has been the safe and efficient delivery of this system to cells/tissues of interest. Several approaches have been investigated to find delivery systems that can attain tissue-targeted delivery, lowering the chances of off-target [PM2] editing. While viral vectors have shown promise for in vitro, in vivo and ex vivo delivery of CRISPR/Cas9; further clinical applications have been restricted due to shortcomings including: limited packaging capacity, difficulties with large-scale production, immunogenicity and insertional mutagenesis. Rapid progress in nonviral delivery vectors, including the use of lipid, polymer, peptide and inorganic nanoparticle-based delivery systems, has established nonviral delivery approaches as a viable alternative to viral vectors. This review will introduce the molecular mechanisms of the CRISPR/Cas9 gene editing system, current strategies for delivering CRISPR/Cas9-based tools, an overview of strategies for overcoming off-target genome editing, and approaches for improving sequence targeting, genome targeting and tissue targeting. We will also highlight current developments and recent clinical trials for the delivery of CRISPR/Cas9. Finally, future directions for overcoming the limitations and adaptation of this technology for clinical trials will be discussed.

show abstract

Polyethyleneimine (PEI) as a Polymer-Based Co-Delivery System for Breast Cancer Therapy

Cited by 22 publications

References 65 publications

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells

Polyethylenimine, an Autophagy-Inducing Platinum-Carbene-Based Drug Carrier with Potent Toxicity towards Glioblastoma Cancer Stem Cells

Hyaluronic acid-based nano drug delivery systems for breast cancer treatment: Recent advances

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing

Contact Info

Product

Resources

About